R&D
뉴로바이오젠은 오랜 경험을 가진 뇌신경질환 전문 연구진 및 임상전문가로
구성된 개발위원단과 함께합니다.
원개발자 & 자문위원
  • 원개발자
  • 자문위원
Ki-Duk Park, Ph.D (Original Inventor)
Principal Research Scientist
Convergence Research Center for Diagnosis, Treatment and Care System of Dementia, Brain Science
Institute, Korea Institute of Science and Technology (KIST)
Professor
Division of Bio-Med Science & Technology KIST School, University of Science and Technology (UST)
Email : kdpark@kist.re.kr
Website : http://dtc.kist.re.kr/kor/researcher/read.php?dcode=R02&id=63
Biosketch
Ph.D, Ki Duk Park is a principal research scientist at Korea Institute of science and technology(KIST). And also he acts as a professor to division of Bio-Med Science & Technology KIST School, University of Science and Technology (UST).
Ki Duk Park received his biotechnology degree and Ph.D from Yonsei university. For Postdoctoral research associate, he completed his internship in university of North Carolina at Chapel Hill, Eshelman School of Pharmacy, Division of Medicinal Chemistry and Natural Products. NC, USA.
Until now, his publications are accompanied over 70 about diagnosis, treatment and Care System of Dementia and brain science.
Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer’s disease
Monoamine oxidase–B (MAO-B) has recently emerged as a potential therapeutic target for Alzheimer’s disease (AD) because of its association with aberrant γ-aminobutyric acid (GABA) production in reactive astrocytes. Although short-term treatment with irreversible MAO-B inhibitors, such as selegiline, improves cognitive deficits in AD patients, long-term treatments have shown disappointing results. We show that prolonged treatment with selegiline fails to reduce aberrant astrocytic GABA levels and rescue memory impairment in APP/PS1 mice, an animal model of AD, because of increased activity in compensatory genes for a GABA-synthesizing enzyme, diamine oxidase (DAO). We have developed a potent, highly selective, and reversible MAO-B inhibitor, KDS2010 (IC50 = 7.6 nM; 12,500-fold selectivity over MAO-A), which overcomes the disadvantages of the irreversible MAO-B inhibitor. Long-term treatment with KDS2010 does not induce compensatory mechanisms, thereby significantly attenuating increased astrocytic GABA levels and astrogliosis, enhancing synaptic transmission, and rescuing learning and memory impairments in APP/PS1 mice.
Chang-Joon Justin Lee, Ph.D (Original Inventor)
Director of Center
Director of Center for Cognition and Sociality, Institute for Basic Science (IBS)
Professor
IBS School of UST, Korea University of Science&Tech
Editor-in-chief
Experimental Neurobiology (EN), The Official Jouranl of Society for Korean Society for Brain and Neural Science (KSBNS)
Email : cjl@ibs.re.kr
Website : http://www.ibs.re.kr/glia
Biosketch
Ph.D, Chang Joon Ha is a director of center for Cognition and Sociality, Institute for Basic Science (IBS). And also he acts as a professor to BS School of UST and Korea University of Science&Tech. As an editor-in-chief, he contributes to Experimental Neurobiology (EN) and The Official Jouranl of Society for Korean Society for Brain and Neural Science (KSBNS).
Chang Joon Ha received his chemistry degree from the University of Chicago, USA and Ph.D. from Columbia University in 2001. For Post doctoral fellow, he completed his internship in Emory University, Atlanta, GA, USA, Department of Pharmacology
Recently his selected publications are accompanied over 12 and its total citations are 5091 as of March 2018. With it, he published 145 journal articles, 3 submitted article and so on.
Obesity and reactive astrocytes: a lesson from Alzheimer’s Disease
The brain regulates feeding by responding to dietary factors and metabolism. In obesity, obese individuals show disrupted energy homeostasis which is crucial for the survival and health of organisms to control hunger and energy balance. Although hypothalamic reactive astrocytes in lateral hypothalamic area (LHA) were observed in high fat diet-induced obese (DIO) mouse model, their role has been poorly understood. Here, we report immunohistochemical, electrophysiological data showing increased level of inhibitory gliotransmitter GABA in reactive astrocytes of DIO mice. We have previously demonstrated that monoamine oxidase-B (MAO-B) is responsible for the synthesis of GABA and Best1 channel for tonic release of GABA in reactive astrocytes in Alzheimer disease model mouse. When DIO mice were administered with a newly developed selective and reversible MAO-B inhibitor (KDS2010) dissolved in drinking water, they showed significantly reduced body mass compared to the groups fed with high fat diet (HFD) and drinking water only. However, total amount of food intake was similar between HFD with KDS2010 group and HFD with water group. These results imply that hypothalamic reactive astrocytes in LHA of the DIO model aberrantly and abundantly synthesize GABA via MAO-B and release via Best1. The astrocytic GABA may alter the activity of neurons for facilitating energy expenditure in DIO model. We propose that selective inhibition of astrocytic GABA synthesis or release may be a potential molecular target for treating obesity without compromising appetite.
Yoon Ha, M.D., Ph.D
Professor
Neurological Surgery in Yonsei University
Editor-in-chief
The Neurospine, Asian spine journal (2017~), Neurosurgery Focus (2017), the Editorial Boards of Neurosurgery (2016)
Email : HAYOON@yuhs.ac
Website : http://www.nssev.ac.kr|http://blog.naver.com/hopekorea
Biosketch
Yoon Ha, MD, PhD received his medical degree and PhD from Yonsei University. He completed his internship and neurosurgery residency at Severance hospital, Yonsei University in 1999. In 2015, Dr. Ha was appointed Professor of Neurological Surgery in Yonsei Univ. Dr. Ha is board certified in the fields of Neurological Surgery.
Dr. Ha has an active research interest in spinal surgery and basic research, particularly in numerous multicenter outcome research studies of spinal deformities, cervical OPLL, spinal cord injury, spinal trauma and tumors involving the spinal column. He has served as an Editor in Chief of “The Neurospine” and editor on the Editorial Boards of Neurosurgery (2016), Neurosurgery Focus (2017), and Asian spine journal (2017 ~).
During his career in medicine, Dr. Ha has won numerous awards for medicine. He has won the Synthes Award for Research in Spinal cord injury and spinal column injury at Congress of Neuyrological Surgeons in 2004 (San Francisco). He received basic science research award in Cervical Spine Research Societies in 2004 (Boston) and 2009 (Salt Lake City).
Dr.Ha’s clinical fields of interest are Adult Spinal Deformity Surgery, Cervical Deformity and Correction Surgery, Cervical OPLL and spondylotic myelopathy, Endoscopic spine surgery for lumbar degenerative disease, Robotic spinal surgery for spine tumor resection and Biologic therapy for Malignant Spinal cord tumor.
Control of Reactive astrocytes for spinal cord regeneration
Neuroregeneration and remyelination after central nervous system (CNS) injury rarely occur in adult mammalian brain and spinal cord. It has been proposed that the main cause of this failure in CNS repair system originates from the glial scar which includes scar-forming reactive astrocytes. However, the molecular and cellular mechanisms of how glial scar impedes CNS repair system is unknown. Here we report that CNS repair system is strongly suppressed by the monoamine oxidase B (MAOB)-dependent excessive GABA production and release from reactive astrocytes in a severe spinal cord injury (SCI) model. A genetic or pharmacological inhibition of MAOB effectively converts the GABA-containing reactive astrocytes to proBDNF-expressing active astrocytes which facilitate neuroregeneration, remyelination and functional recovery after SCI. Particularly, a treatment with KDS2010, a newly-developed, reversible MAOB inhibitor, results in not only a marked increase in astrocytic and neuronal proBDNF, but also a significant increase in astrocytic, neuronal, and oligodendrocytic TrkB, the receptor for mature BDNF (mBDNF). Our findings propose MAOB as a highly effective therapeutic target for SCI and KDS2010 as a next-generation drug candidate for SCI.
Seol-Heui Han, M.D., Ph.D.
Professor Emeritus
Department of Neurology, Konkuk University Hospital
Email : 20050102@kuh.ac.kr
Educational History
1973 - 1975: Sung Kyun Kwan University, Seoul. Major – Economics
1975 - 1981: Seoul National University, College of Medicine. Major – Medicine. M.D. awarded 2/81
1986 - 1988: Seoul National University, Seoul. M.A. awarded 2/88
1989 - 1991: Seoul National University, Seoul. Ph.D. awarded, 2/91
Professional Society
- Member of Koran Neurological Association since 1985.
- President of the Korean Dementia Association since 2002
- Member of the International Society for Vascular Behavioral and Cognitive Disorders since 2007
- Editorial Board Member, Alzheimer’s Disease and Associated Disorders, 2004-2006
- Member of the International Society to Advance Alzheimer Research and Treatment (ISTAART)
- Secretary for Foreign Affairs of the Korean Neurological Association (past)
- President, Korean Dementia Association: 2002-2006
- Chairman, Korean Dementia Association: 2008-2012
- Chairman, Korean Geriatric Neurology Association: 2016-2018
Major Research Interest
1. Molecular pathogenesis of Alzheimer’s disease.
2. Animal Models for Dementia.
3. Mechanisms of Neuronal Death
4. Neurotoxicology
5. Clinical Trials of Alzheimer’s disease
Hyoung-Ihl Kim, M.D., Ph.D
Professor
Neuromodulation Lab Departmernt of Biomedical Science and Engineering Gwanju Institute of Science & Techgnology (GIST)
Email : hyoungihl@gist.ac.kr
Website : http://neuro.gist.ac.kr
Biosketch
Dr. Hyoung-Ihl Kim is a neurosurgeon and a professor at GIST. Now running “Neuromodulation Lab” in GIST. His research focuses on stroke and neuromodulation technologies. He studied medicine, and received neurosurgical training at Chonbuk National University, 1973-1984. He received epilepsy surgery training in Montreal Neurological Institute, 1990-1991. Since then, he has been involved in functional neurosurgery at Chonbuk National University Hospital and Presbyterian Medical Center at Jeonju, Korea (1991-2009). He moved to GIST in 2010 to continue the basic research related with neuromodulation for human degenerative diseases.
Excessive Astrocytic GABA Causes Cortical Hypometabolism and Impedes Functional Recovery after Subcortical Stroke
Stroke has been a disastrous event to human life and remains the challenging task to be overcome. Previous stroke research has been exclusively focused on the gray matter, which does not comprehensively include the other important components of the brain such as white matter & glia. Recently, we created a photothrombotic capsular infarct model and evaluated stroke recovery using KDS2010.
In this talk, the validity and usefulness of this model with detailed characterization of the model. Next ,we determined the behavioral and imaging biomarkers which can be used to evaluate the degree of stroke recovery. We also demonstrated the effect of various neuromodulation method to augment the post-stroke recovery coupled with the longitudinal change of accompanying biomarkers. KDS2010 showed the decrease of cortical diaschisis and strengthening of subcortical activations, which are related with capsular infarct. This treatment also showed the enhancement of daily reach behaviors. Immunological studies also showed reversal of cortical GABA. Based on these studies, we propose the feasible strategy of neuromodulation techniques to augment the recovery of stroke disability using KDS2010.
SeungHwan Lee, M.D., Ph.D.
Clinical Associate Professor
Department of Clinical Pharmacology and Therapeutics Head, Quality Improvement Office, Clinical Trials Center, Seoul National University Hospital
Email : leejh413@snu.ac.kr
Biosketch
Dr. Lee is currently a Clinical Associate Professor of Department of Clinical Pharmacology and Therapeutics and the Head of Quality Improvement Office of Clinical Trials Center in Seoul National University Hospital (SNUH).
After graduating from Seoul National University College of Medicine, he completed internship at SNUH and went on to be trained in the clinical pharmacology residency program at SNU/SNUH. He received his Ph.D. from this university in 2012, and has been involved in many clinical pharmacology research projects since training.
He is interested in various topics related to early phase clinical trials, PK-PD modeling & clinical trial simulation, and individualized pharmacotherapy.
Recently, Dr. Lee has been participating in more than twenty clinical research projects annually, as principal investigator or co-investigator. Some are investigator-sponsored trials, and others are those sponsored by multinational or domestic pharmaceutical companies. These projects involve drugs and biologic products regarding a wide range of therapeutic areas, and span over various kinds of study types such as first-in-human (FIH) studies, PK-PD studies, drug-drug interaction (DDI) studies, new formulation evaluations, clinical pharmacogenomic (PGx) studies, and PK-PD support in phase 2 or 3 trials. He is also giving many consultations regarding clinical drug development.